<DOC>
	<DOCNO>NCT00833261</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving cetuximab cisplatin together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give cetuximab cisplatin together radiation therapy work treat patient recurrent head neck cancer .</brief_summary>
	<brief_title>Cetuximab , Cisplatin , Radiation Therapy Treating Patients With Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate whether treatment cetuximab , cisplatin , intensity-modulated radiotherapy improve overall survival patient recurrent squamous cell carcinoma head neck . Secondary - To determine progression-free survival local-regional progression patient . - To identify estimate incidence rate acute late toxicity associate treatment regimen . - To determine pattern disease progression patient . OUTLINE : This multicenter study . Patients receive cetuximab IV 60-120 minute weekly week 1-7 . Patients also receive cisplatin IV 60 minute weekly undergo intensity-modulated radiotherapy daily 5 day week week 2-7 . After completion study treatment , patient follow every 3 month 2 year every 6 month 4 year .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm squamous cell carcinoma ( SCC ) upper aerodigestive tract Recurrent disease second primary SCC Recurrence second primary must confine head neck clavicle ( locoregional recurrence ) Majority ( ≥ 75 % ) recurrent tumor must area previously irradiate ≥ 45 Gy More one recurrence allow provide first recurrence occur &gt; 6 month completion prior radiotherapy Unresectable disease OR highrisk feature resection ( e.g. , positive margin and/or extracapsular extension ) No sign carotid exposure No primary nasopharyngeal salivary gland tumor Equivocal pulmonary node chest CT scan allow provide &lt; 1 cm , safely biopsied , negative PET scan No distant metastasis PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % ANC ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL ( transfusion intervention allow ) Bilirubin &lt; 1.5 mg/dL AST ALT &lt; 2 time upper limit normal Creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able submit prior radiotherapy record assure spinal cord tolerance exceed No active cardiac disease , include follow : Unstable angina Uncontrolled hypertension Myocardial infarction within past 6 month ( unless successfully treat coronary artery bypass graft percutaneous transluminal coronary angioplasty ) Uncontrolled arrhythmia Congestive heart failure At least 3 heartrelated hospitalization within past year No severe chronic obstructive pulmonary disease require ≥ 3 hospitalization within past year No concurrent medical illness would impair patient tolerance therapy limit survival No invasive malignancy within past 2 year No preexist peripheral sensory neuropathy ≥ grade 2 No prior severe infusion reaction monoclonal antibody No prisoner individual compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior surgery Prior cisplatin cetuximab allow At least 6 month since prior radiotherapy chemotherapy No prior radiotherapy &gt; 75 Gy No prior chemotherapy recurrent head neck cancer Prior chemotherapy component primary treatment allow No prior combination cisplatin , cetuximab , radiotherapy recurrent head neck cancer Patients new primary head neck cancer whose prior primary head neck cancer treat concurrent cisplatin , cetuximab , radiotherapy eligible provide &gt; 6 month since treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>tongue cancer</keyword>
</DOC>